Risks and benefits of phase I liver dysfunction studies: should patients with severe liver dysfunction be included in these trials?

Christos Fountzilas, Selena Stuart, Brian Hernandez, Elizabeth Bowhay-Carnes, Joel Michalek, John Sarantopoulos, Anand Karnad, Sukeshi Patel, Steven Weitman, Devalingam Mahalingam*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Fingerprint

Dive into the research topics of 'Risks and benefits of phase I liver dysfunction studies: should patients with severe liver dysfunction be included in these trials?'. Together they form a unique fingerprint.

Medicine and Dentistry

INIS

Pharmacology, Toxicology and Pharmaceutical Science